NL8020195A - Werkwijze ter bereiding van thymosine alfa1 en derivaten daarvan. - Google Patents
Werkwijze ter bereiding van thymosine alfa1 en derivaten daarvan. Download PDFInfo
- Publication number
- NL8020195A NL8020195A NL8020195A NL8020195A NL8020195A NL 8020195 A NL8020195 A NL 8020195A NL 8020195 A NL8020195 A NL 8020195A NL 8020195 A NL8020195 A NL 8020195A NL 8020195 A NL8020195 A NL 8020195A
- Authority
- NL
- Netherlands
- Prior art keywords
- glu
- lys
- fragment
- thymosin
- ddz
- Prior art date
Links
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 title claims description 13
- 102000007501 Thymosin Human genes 0.000 title claims description 12
- 108010046075 Thymosin Proteins 0.000 title claims description 12
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000012634 fragment Substances 0.000 claims description 54
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 25
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 24
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 150000001408 amides Chemical class 0.000 claims description 14
- 238000009833 condensation Methods 0.000 claims description 13
- 230000005494 condensation Effects 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- 125000006239 protecting group Chemical class 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 102000007079 Peptide Fragments Human genes 0.000 claims description 9
- 108010033276 Peptide Fragments Proteins 0.000 claims description 9
- -1 4,4'-dimethylbenzhydryl protecting group Chemical group 0.000 claims description 8
- 210000004899 c-terminal region Anatomy 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000004185 ester group Chemical group 0.000 claims description 6
- 150000004702 methyl esters Chemical class 0.000 claims description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 5
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 230000007017 scission Effects 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 3
- 238000006386 neutralization reaction Methods 0.000 claims description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 101800001415 Bri23 peptide Proteins 0.000 claims description 2
- 102400000107 C-terminal peptide Human genes 0.000 claims description 2
- 101800000655 C-terminal peptide Proteins 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 7
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 7
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 claims 3
- 229940024606 amino acid Drugs 0.000 claims 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- NLNCNKIVJPEFBC-DLOVCJGASA-N Val-Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O NLNCNKIVJPEFBC-DLOVCJGASA-N 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004900 c-terminal fragment Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000007127 saponification reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102400000454 Insulin B chain Human genes 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- YSMHTFWPDRJCMN-UHFFFAOYSA-N butan-2-yl carbonochloridate Chemical compound CCC(C)OC(Cl)=O YSMHTFWPDRJCMN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57581—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/18—Thymus derived hormone or factor; related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19792919592 DE2919592A1 (de) | 1979-05-15 | 1979-05-15 | Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon |
| DE2919592 | 1979-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8020195A true NL8020195A (nl) | 1981-02-27 |
Family
ID=6070778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8020195A NL8020195A (nl) | 1979-05-15 | 1980-05-14 | Werkwijze ter bereiding van thymosine alfa1 en derivaten daarvan. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US4353821A (OSRAM) |
| EP (1) | EP0028627B1 (OSRAM) |
| JP (1) | JPH0135840B2 (OSRAM) |
| CH (1) | CH649089A5 (OSRAM) |
| DE (1) | DE2919592A1 (OSRAM) |
| GB (1) | GB2065662B (OSRAM) |
| NL (1) | NL8020195A (OSRAM) |
| WO (1) | WO1980002560A1 (OSRAM) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0033384B1 (de) * | 1980-01-18 | 1984-02-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Thymosin-alpha-1-Fragmente enthaltende Arzneimittel mit immunstimulierender Wirkung, und Thymosin-alpha-1-Fragmente |
| DE3137231A1 (de) * | 1981-09-18 | 1983-04-14 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Bis-thymosin(alpha)(pfeil abwaerts)1(pfeil abwaerts)-verbindungen |
| US4497801A (en) * | 1982-09-17 | 1985-02-05 | Fujisawa Pharmaceutical Co., Ltd. | New peptides, process for preparation thereof and use thereof |
| US4581168A (en) * | 1983-02-21 | 1986-04-08 | Sanofi | Synthesis of hpGRF (Somatocrinin) in liquid phase and intermediate peptides |
| US4517119A (en) * | 1983-04-04 | 1985-05-14 | Hoffmann-La Roche Inc. | Synthesis of thymosin α1 |
| US4504415A (en) * | 1983-04-04 | 1985-03-12 | Hoffman-La Roche Inc. | Synthesis of thymosin α1 and desacetyl thymosin α1 |
| FR2551088B1 (OSRAM) * | 1983-08-29 | 1985-12-06 | Pasteur Institut | |
| US4983387A (en) * | 1986-05-19 | 1991-01-08 | Viral Technologies Inc. | HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus |
| ZA873215B (en) * | 1986-05-19 | 1987-10-28 | Viral Technologies Inc. | Htlv-iii/lav virus related peptides,antibodies to the peptides,vaccines,passive and active immunization against aids virus and diagnostic test for the serological detection of aids virus |
| US5807830A (en) * | 1987-12-30 | 1998-09-15 | Cytoven J.V. | Method for treatment of purulent inflammatory diseases |
| US5728680A (en) | 1987-12-30 | 1998-03-17 | Cytoven J.V. | Methods for normalizing numbers of lymphocytes |
| US5811399A (en) * | 1988-12-14 | 1998-09-22 | Cytran, Inc. | Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants |
| US5770576A (en) * | 1989-08-30 | 1998-06-23 | Cytran, Inc. | Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity |
| US6066622A (en) | 1991-10-28 | 2000-05-23 | Cytran, Inc. | Immunomodulating peptides and methods of use |
| US6100380A (en) * | 1991-10-28 | 2000-08-08 | Cytran, Inc. | Immunomodulating peptides and methods of use |
| CN1058500C (zh) * | 1993-02-03 | 2000-11-15 | 施塞克龙药品公司 | 胸腺素α－1衍生物 |
| AU6359594A (en) * | 1993-03-04 | 1994-09-26 | Cytoven International N.V. | Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof |
| US6262230B1 (en) * | 1994-01-28 | 2001-07-17 | Sciclone Pharmaceuticals Inc. | Analogs of thymosin α1 |
| US5632983A (en) | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
| AU2001268326A1 (en) * | 2000-06-14 | 2001-12-24 | Chanda Zaveri | Peptides with physiological activity |
| US20070031372A1 (en) * | 2004-08-05 | 2007-02-08 | Hadden John W | Vaccine immunotherapy for immune suppressed patients |
| US20070154399A1 (en) * | 2000-10-27 | 2007-07-05 | Hadden John W | Immunotherapy for immune suppressed patients |
| US20060194242A1 (en) * | 2000-10-27 | 2006-08-31 | Hadden John W | Immunotherapy for immune suppressed patients |
| US7182942B2 (en) * | 2000-10-27 | 2007-02-27 | Irx Therapeutics, Inc. | Vaccine immunotherapy for immune suppressed patients |
| US20070025958A1 (en) * | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
| EP1337149A4 (en) | 2000-10-27 | 2005-10-12 | Irx Therapeutics Inc | VACCINE IMMUNOTHERAPY FOR IMMUNE-PATIENT PATIENTS |
| US20050020495A1 (en) * | 2001-10-24 | 2005-01-27 | Martins Eduardo Bruno Guimaraes | Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors |
| JP2005510491A (ja) * | 2001-10-26 | 2005-04-21 | イミュノ−アールエックス， インコーポレイテッド | 免疫抑制を逆転させるための免疫治療 |
| CN1269524C (zh) * | 2001-10-26 | 2006-08-16 | 罗得岛医院 | 胸腺素强化的遗传免疫方法 |
| UA78726C2 (en) * | 2001-11-01 | 2007-04-25 | Sciclone Pharmaceuticals Inc | Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment |
| UA77999C2 (en) * | 2001-12-10 | 2007-02-15 | Thymosin-alpha 1 for treatment of malignant glioblastoma | |
| CN100501400C (zh) | 2002-11-25 | 2009-06-17 | 希克龙制药公司 | 使用α胸腺素防护辐射损伤的方法 |
| UA80870C2 (en) * | 2003-03-28 | 2007-11-12 | Sciclone Pharmaceuticals Inc | Method for treatment or prevention of aspergillus infections with thymosin alpha 1 |
| US20100311656A1 (en) * | 2003-04-23 | 2010-12-09 | Sciclone Pharmaceuticals, Inc. | Treatment or prevention of respiratory viral infections with alpha thymosin peptides |
| MXPA06000517A (es) * | 2003-07-18 | 2006-07-10 | Regenerx Biopharmaceuticals | Composiciones y metodos para el tratamiento o prevencion de dano debido a la exposicion a radiacion. |
| WO2009070639A1 (en) | 2007-11-28 | 2009-06-04 | Irx Therapeutics, Inc. | Method of increasing immunological effect |
| ES2679043T3 (es) | 2009-05-15 | 2018-08-21 | Irx Therapeutics, Inc. | Inmunoterapia de vacuna |
| CN107050430B (zh) | 2009-12-08 | 2021-10-15 | 伊尔克斯治疗有限公司 | 逆转朗格汉斯细胞免疫抑制的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4079127A (en) * | 1976-10-28 | 1978-03-14 | Board Of Regents Of The University Of Texas | Thymosin alpha 1 |
| CH633258A5 (en) * | 1976-10-28 | 1982-11-30 | Hoffmann La Roche | Process for preparing thymosin alpha 1 |
| US4116951A (en) * | 1977-04-22 | 1978-09-26 | Hoffmann-La Roche Inc. | [Asn2 ]-thymosin α1 and analogs thereof |
| CH641152A5 (en) * | 1977-04-22 | 1984-02-15 | Hoffmann La Roche | Process for preparing thymosin alpha-1 and an analogue |
| US4148788A (en) * | 1978-01-23 | 1979-04-10 | Hoffmann-La Roche Inc. | Synthesis of thymosin α1 |
| DE2830442A1 (de) * | 1978-07-11 | 1980-01-24 | Max Planck Gesellschaft | Verfahren zur herstellung von polypeptiden |
-
1979
- 1979-05-15 DE DE19792919592 patent/DE2919592A1/de active Granted
-
1980
- 1980-03-24 US US06/133,031 patent/US4353821A/en not_active Expired - Lifetime
- 1980-05-14 NL NL8020195A patent/NL8020195A/nl not_active Application Discontinuation
- 1980-05-14 GB GB8038854A patent/GB2065662B/en not_active Expired
- 1980-05-14 JP JP55501235A patent/JPH0135840B2/ja not_active Expired
- 1980-05-14 CH CH230/81A patent/CH649089A5/de not_active IP Right Cessation
- 1980-05-14 WO PCT/DE1980/000067 patent/WO1980002560A1/de active IP Right Grant
- 1980-12-01 EP EP80901003A patent/EP0028627B1/de not_active Expired
-
1982
- 1982-07-29 US US06/403,218 patent/US4466918A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0135840B2 (OSRAM) | 1989-07-27 |
| WO1980002560A1 (en) | 1980-11-27 |
| CH649089A5 (de) | 1985-04-30 |
| US4466918A (en) | 1984-08-21 |
| GB2065662A (en) | 1981-07-01 |
| US4353821A (en) | 1982-10-12 |
| EP0028627A1 (de) | 1981-05-20 |
| GB2065662B (en) | 1983-03-30 |
| JPS56500655A (OSRAM) | 1981-05-14 |
| DE2919592A1 (de) | 1981-01-15 |
| DE2919592C2 (OSRAM) | 1992-01-16 |
| EP0028627B1 (de) | 1984-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL8020195A (nl) | Werkwijze ter bereiding van thymosine alfa1 en derivaten daarvan. | |
| Marshall et al. | Synthesis of angiotensins by the solid-phase method | |
| CA2042001C (en) | Peptide amides, processes for the preparation thereof and agents containing these as fibrin/thrombin clotting inhibitors | |
| Carpino et al. | [(9-Fluorenylmethyl) oxy] carbonyl (Fmoc) amino acid chlorides in solid-phase peptide synthesis | |
| JP2679786B2 (ja) | 非ペプチド結合を有するペプチド合成方法 | |
| US4261886A (en) | Peptides having thymopoietin-like activity | |
| JP5908478B2 (ja) | ｈ「Ｇｌｙ２」ＧＬＰ−２の固相合成 | |
| DK149754B (da) | Analogifremgangsmaade til fremstilling af et dermorphinanalogt tetra-, penta-, hexa- eller heptapeptidderivat eller et farmaceutisk acceptabelt salt deraf | |
| CN1038034C (zh) | 肽模拟物的快速合成和筛选 | |
| US4098777A (en) | Process for the preparation of pyroglutamyl-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn | |
| Blake et al. | THE SOLID‐PHASE SYNTHESIS OF ALPHA‐MELANOTROPIN | |
| NO149998B (no) | Analogifremgangsmaate til fremstilling av peptider med ubiquitinlignende aktivitet | |
| US5059679A (en) | Method of selectively sulfating peptides | |
| CA1157466A (en) | Peptides having thymopoietin-like activity | |
| WO1994018233A1 (en) | Thymosin alpha-1 derivatives | |
| Wong et al. | Synthesis of a fully active snake venom cardiotoxin by fragment condensation on solid polymer | |
| HU185238B (en) | Process for preparing peptides containing guanidino-group | |
| US4301045A (en) | Synthesis of peptides | |
| US3886137A (en) | P-Glu-D-Phe-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-Gly-NH{HD 2 {B and intermediates | |
| US3890437A (en) | Method of inhibiting fertility in mammals using D{13 Phe{hu 2{b {13 D{13 Ala{hu 6{b {13 LRF | |
| RU2091389C1 (ru) | Пептид, обладающий иммуномодулирующей активностью | |
| US4242238A (en) | Synthesis of peptides | |
| STÜBER et al. | Synthesis and photolytic cleavage of bovine insulin B22–30 on a nitrobenzoylglycyl‐poly (ethylene glycol) support | |
| Eckstein et al. | Synthesis of peptide gels for the investigation of oligopeptide–oligonucleotide interactions | |
| Hashimoto et al. | Neurokinin B analogs substituted with glycine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| CNR | Transfer of rights (patent application after its laying open for public inspection) |
Free format text: ORGANOGEN MEDIZINISCH-MOLEKULARBIOLOGISCHE |
|
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| DNT | Communications of changes of names of applicants whose applications have been laid open to public inspection |
Free format text: ORPEGEN MEDIZINISCH-MOLEKULARBIOLOGISCHE |
|
| BV | The patent application has lapsed |